Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 3-10 , February 2003

Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia

  • Uday Popat
    • ,
  • George Carrum
    • ,
  • Helen E Heslop

      Affiliations

    • Corresponding Author InformationCorrespondence to: Helen E. Heslop, Departments of Medicine and Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, 1102 Bates St., Suite 1140 Houston, TX 77030, USA. Tel: +832-824-4662; Fax: +832-825-4668

References 

  1. Yeoh EJ, Ross ME, Shurtleff SA, et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukaemia by gene expression profiling. Cancer Cell. 2002;1:133–143
  2. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N. Engl. J. Med. 1998;339:605–615
  3. Wheeler KA, Richards SM, Bailey CC, et al.  Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukaemia in first remission: results from Medical Research Council UKALL X and XI. Blood. 2000;96:2412–2418
  4. Arico M, Valsecchi MG, Camitta B, et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia. N. Engl. J. Med. 2000;342:998–1006
  5. Pui CH, Gaynon PS, Boyett JM, et al.  Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909–1915
  6. www.ibmtr.org. Int Bone Marrow Transplant Registry 2002
  7. Sebban C, Lepage E, Vernant JP, et al.  Allogeneic bone marrow transplantation in adult acute lymphoblastic leukaemia in first complete remission: a comparative study. French Group of Therapy of Adult acute Lymphoblastic Leukaemia. J. Clin. Oncol. 1994;12:2580–2587
  8. Chao NJ, Forman SJ, Schmidt GM, et al.  Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukaemia during first complete remission. Blood. 1991;78:1923–1927
  9. Thiebaut A, Vernant JP, Degos L, et al.  Adult acute lymphocytic leukaemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Haematol. Oncol. Clin. North Am. 2000;14:1353–1366
  10. Barrett AJ, Horowitz MM, Pollock BH, et al.  Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission. N. Engl. J. Med. 1994;332:823–824
  11. Harrison G, Richards S, Lawson S, et al.  Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. Ann. Oncol. 2000;11:999–1006
  12. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br. J. Haematol. 1998;101:94–103
  13. Wagner JE, Anasetti C, Kollman C, et al. Unrelated donor bone marrow transplantation in 5075 patients with malignant and non-malignant disease: Effect of graft-versus-host-disease prophylaxis on treatment outcome. 2002 [in press]
  14. Goldman FD, Rumelhart SL, DeAlacron P, et al.  Poor outcome in children with refractory/relapsed leukaemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant. 2000;25:943–948
  15. Biggs JC, Horowitz MM, Gale RP, et al.  Bone marrow transplants may cure patients with acute leukaemia never achieving remission with chemotherapy. Blood. 1992;80:1090–1093
  16. NMDP online. www.nmdp.org 2002
  17. Hongeng S, Krance RA, Bowman LC, et al.  Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997;350:767–770
  18. Oakhill A, Pamphilon DH, Potter MN, et al.  Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br. J. Haematol. 1996;94:574–578
  19. Saarinen-Pihkala UM, Gustafsson G, Ringden O, et al.  No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukaemia in second remission. J. Clin. Oncol. 2001;19:3406–3414
  20. Al Kasim FA, Thornley I, Rolland M, et al.  Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br. J. Haematol. 2002;116:483–490
  21. Woolfrey AE, Anasetti C, Storer B, et al.  Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukaemia in children. Blood. 2002;99:2002–2008
  22. Bunin N, Carston M, Wall D, et al.  Unrelated marrow transplantation for children with acute lymphoblastic leukaemia in second remission. Blood. 2002;99:3151–3157
  23. Aversa F, Tabilio A, Velardi A, et al.  Treatment of high-risk acute leukaemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 1998;339:1186–1193
  24. Handgretinger R, Schumm M, Lang P, et al.  Transplantation of megadoses of purified haploidentical stem cells. Ann. N. Y. Acad. Sci. 1999;872:351–361
  25. Guinan EC, Boussiotis VA, Neuberg D, et al.  Transplantation of anergic histoincompatible bone marrow allografts [see comments]. N. Engl. J. Med. 1999;340:1704–1714
  26. Weisdorf DJ, Billett AL, Hannan P, et al.  Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukaemia. Blood. 1997;90:2962–2968
  27. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al.  Use of partially mismatched related donor extends access to allogenic marrow transplant. Blood. 1997;89:3864–3872
  28. Attal M, Blaise D, Marit G, et al.  Consolidation treatment of adult acute lymphoblastic leukaemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood. 1995;86:1619–1628
  29. Bensinger WI, Weaver CH, Appelbaum FR, et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85:1655–1658
  30. Korbling M, Przepiorka D, Huh YO, et al.  Allogeneic blood stem cell transplantation for refratory leukaemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995;85:1659–1665
  31. Bensinger W, Martin P, Storer B, et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with haematologic cancers. N. Engl. J. Med. 2001;344:175–181
  32. Couban S, Simpson DR, Barnett MJ, et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100:1525–1531
  33. Champlin RE, Schmitz N, Horowitz MM, et al.  Blood stem cells compared with bone marrow as a source of haematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702–3709
  34. Rubinstein P, Carrier C, Scaradavou A, et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N. Engl. J. Med. 1998;339:1565–1577
  35. Gluckman E, Rocha V, Boyer-Chammard A, et al.  Outcome of cord-blood transplantation from related and unrelated donors. N. Engl. J. Med. 1997;337:373–381
  36. Rocha V, Cornish J, Sievers E, et al.  Comparison of outcomes of unrelated bone marrow and umbliical cord blood transplants in children with acute leukaemia. Blood. 2002;97:2962–2971
  37. Locatelli F, Rocha V, Chastang C, et al.  Factors associated with outcome after cord blood transplantation in children with acute leukaemia. Eurocord–Cord Blood Transplant Group. Blood. 1999;93:3662–3671
  38. Davies SM, Ramsay NK, Klein JP, et al.  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukaemia. J. Clin. Oncol. 2000;18:340–347
  39. Slavin S, Nagler A, Naparstek E, et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematologic diseases. Blood. 1998;91:756–763
  40. Giralt S, Thall PF, Khouri I, et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with haematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  41. Khouri IF, Keating M, Korbling M, et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 1998;16:2817–2824
  42. Storb R, Yu C, Deeg HJ, et al.  Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann. N. Y. Acad. Sci. 1998;850:276–287
  43. Kottaridis PD, Milligan DW, Chopra R, et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation [in process citation]. Blood. 2000;96:2419–2425
  44. Wulf GG, Rill DR, Luo K-L, et al. Complement fixing monoclonal antibodies to facilitate stem cell transplantation in mice. Ann N Y Acad Sci [in press]
  45. Nash RA, Pineiro LA, Storb R, et al.  FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88:3634–3641
  46. Champlin RE, Passweg JR, Zhang MJ, et al.  T-cell depletion of bone marrow transplants for leukaemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95:3996–4003
  47. Porter DL, Antin JH. The graft-versus-leukaemia effects of allogeneic cell therapy. Annu. Rev. Med. 1999;50:369–386
  48. Ottmann OG, Wassmann B, Pfeifer H, et al.  Activity of the ABL-Tyrosine Kinase Inhibitor Glivec (STI571) in Philadelphia Chromosome Positive Acute Lymphoblstic Leukaemia (PH+ ALL) Relapsing after Allogeneic stem cell transplantation (allo-SCT). Blood. 2002;98(11):589a
  49. Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia. Blood. 2001;98:1982–1984
  50. Locatelli F, Zecca M, Rondelli R, et al.  Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukaemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95:1572–1579
  51. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukaemia with ex vivo- generated cytotoxic T lymphocytes specific for haematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336–2341
  52. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukaemia cells by a CD8(+) cytotoxic T- lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286–293
  53. Cardoso AA, Seamon MJ, Alfonso HM, et al.  Ex vivo generation of human anti-pre-B leukaemia-specific autologous cytolytic T cells. Blood. 1997;90:549–561
  54. Dilloo D, Bacon K, Holden W, et al.  Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 1996;2:1090–1095
  55. Rousseau RF, Bollard CM, Heslop HE. Gene therapy for paediatric leukaemia. Expert. Opin. Biol. Ther. 2001;1:663–674
  56. Dekker AW, Vant Veer MG, Van der Holt B, et al.  Postremission treatment with autologous stem cell transplantation (Auto-SCT) or Allogeneic stem cell transplantation (Allo-SCT) in adults with Acute Lymphoblastic Leukaemia (ALL). A Phase II Clinical trial (HOVON 18 ALL). Blood. 2002;98:
  57. Rowe JM, Richards SM, Burnett AK, et al.  Favorable results of Allogeneic Bone Marrow Transplantation (BMT) for Adults with Philadelphia (Ph)-chromosome-negative Acute Lymphoblastic Leukaemia (ALL) in first complete remission (CR): results from the International ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2001;98:
  58. Goldstone AH, Prentice HG, Durrant JI, et al.  Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) Acute Lymphoblastic Leukaemia (ALL). Results from the international ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2002;98
  59. Zhang MJ, Hoelzer D, Horowitz MM, et al.  Long-term follow-up of adults with acute lymphoblastic leukaemia in first remission treated with chemotherapy or bone marrow transplantation: the Acute Lymphoblastic Leukaemia Working Committee. Ann. Int. Med. 1995;123:428–431
  60. Oh H, Gale RP, Zhang MJ, et al.  Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukaemia in first remission. Bone Marrow Transplant. 1998;22:253–257

PII: S0305-7372(02)00092-0

doi: 10.1016/S0305-7372(02)00092-0

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 3-10 , February 2003

Article Tools